J. Friedman and V. Riccardi, Clinical and Epidemiological Features In Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, pp.29-86, 1999.

M. Upadhyaya and D. Cooper, Neurofibromatosis Type 1: Molecular and Cellular Biology, 2012.
DOI : 10.1007/978-3-642-32864-0

A. Graf, M. Landolt, A. Mori, and E. Boltshauser, Quality of life and psychological adjustment in children and adolescents with neurofibromatosis type 1, The Journal of Pediatrics, vol.149, issue.3, pp.348-353, 2006.
DOI : 10.1016/j.jpeds.2006.04.025

K. North, D. Gutmann, M. Maccollin, and V. Riccardi, Cognitive Function and Academic Performance, Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, p.380, 1999.

N. Pride and K. North, The Cognitive Profile of NF1 Children: Therapeutic Implications, In Neurofibromatosis Type Molecular and Cellular Biology, vol.1, issue.2012, p.55
DOI : 10.1007/978-3-642-32864-0_5

N. Pride, J. Payne, and K. North, The Impact of ADHD on the Cognitive and Academic Functioning of Children With NF1, Developmental Neuropsychology, vol.6, issue.7, pp.590-600, 2012.
DOI : 10.1016/S0140-6736(10)61109-9

A. Obringer, A. Meadows, and E. Zackai, The Diagnosis of Neurofibromatosis-1 in the Child Under the Age of 6 Years, Archives of Pediatrics & Adolescent Medicine, vol.143, issue.6, pp.717-719, 1989.
DOI : 10.1001/archpedi.1989.02150180099028

D. Gutmann, A. Aylsworth, J. Carey, B. Korf, J. Marks et al., The Diagnostic Evaluation and Multidisciplinary Management of Neurofibromatosis 1 and Neurofibromatosis 2, JAMA: The Journal of the American Medical Association, vol.278, issue.1, pp.51-57, 1997.
DOI : 10.1001/jama.1997.03550010065042

S. Hyman, A. Shores, and K. North, The nature and frequency of cognitive deficits in children with neurofibromatosis type 1, Neurology, vol.65, issue.7, pp.1037-1044, 2005.
DOI : 10.1212/01.wnl.0000179303.72345.ce

B. Moore, J. Ater, M. Needle, J. Slopis, and D. Copeland, Neuropsychological Profile of Children With Neurofibromatosis, Brain Tamor, or Both, Journal of Child Neurology, vol.9, issue.4, pp.368-377, 1994.
DOI : 10.1177/088307389400900406

R. Ferner, R. Hughes, and J. Weinman, Intellectual impairment in neurofibromatosis 1, Journal of the Neurological Sciences, vol.138, issue.1-2, pp.125-133, 1996.
DOI : 10.1016/0022-510X(96)00022-6

C. Dilts, J. Carey, J. Kircher, R. Hoffman, D. Creel et al., Children and Adolescents with Neurofibromatosis 1, Journal of Developmental & Behavioral Pediatrics, vol.17, issue.4, pp.229-239, 1996.
DOI : 10.1097/00004703-199608000-00004

N. Johnson, H. Saal, A. Lovell, and E. Schorry, Social and emotional problems in children with neurofibromatosis type 1: Evidence and proposed interventions, The Journal of Pediatrics, vol.134, issue.6, pp.767-772, 1999.
DOI : 10.1016/S0022-3476(99)70296-9

V. Mautner, L. Kluwe, S. Thakker, and R. Leark, Treatment of ADHD in neurofibromatosis type 1, Developmental Medicine & Child Neurology, vol.98, issue.Suppl. 5, pp.164-170, 2002.
DOI : 10.1111/j.1469-8749.2002.tb00780.x

A. Kayl and B. Moore, Behavioral phenotype of neurofibromatosis, type 1, Mental Retardation and Developmental Disabilities Research Reviews, vol.37, issue.2, pp.117-124, 2000.
DOI : 10.1002/1098-2779(2000)6:2<117::AID-MRDD5>3.0.CO;2-X

F. Coude, C. Mignot, S. Lyonnet, and A. Munnich, Early Grade Repetition and Inattention Associated With Neurofibromatosis Type 1, Journal of Attention Disorders, vol.11, issue.2, pp.101-105, 2007.
DOI : 10.1177/1087054707299398

K. Lidzba, S. Granstrom, J. Lindenau, and V. Mautner, The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1, Developmental Medicine & Child Neurology, vol.31, issue.10, pp.892-899
DOI : 10.1111/j.1469-8749.2012.04377.x

V. Engert and J. Pruessner, Dopaminergic and Noradrenergic Contributions to Functionality in ADHD: The Role of Methylphenidate, Current Neuropharmacology, vol.6, issue.4, pp.322-328, 2008.
DOI : 10.2174/157015908787386069

A. Gilmore and R. Milne, Methylphenidate in children with hyperactivity: review and cost-utility analysis, Pharmacoepidemiology and Drug Safety, vol.34, issue.2, pp.85-94, 2001.
DOI : 10.1002/pds.564

H. Schachter, B. Pham, J. King, S. Langford, and D. Moher, How efficacious and safe is short-acting methylphenidate for the treatment of attentiondeficit disorder in children and adolescents? A meta-analysis, CMAJ, vol.165, pp.1475-1488, 2001.

R. Schachar, A. Jadad, M. Gauld, M. Boyle, L. Booker et al., Attention-Deficit Hyperactivity Disorder: Critical Appraisal of Extended Treatment Studies, The Canadian Journal of Psychiatry, vol.347, issue.2, pp.337-348, 2002.
DOI : 10.1001/jama.1995.03520290060030

L. Greenhill, R. Findling, and J. Swanson, A Double-Blind, Placebo-Controlled Study of Modified-Release Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder, PEDIATRICS, vol.109, issue.3, p.39, 2002.
DOI : 10.1542/peds.109.3.e39

R. Brown, K. Borden, M. Wynne, A. Spunt, and S. Clingerman, Compliance With Pharmacological and Cognitive Treatments for Attention Deficit Disorder, Journal of the American Academy of Child & Adolescent Psychiatry, vol.26, issue.4, pp.521-526, 1987.
DOI : 10.1097/00004583-198707000-00010

A. Charach, A. Ickowicz, and R. Schachar, Stimulant Treatment Over Five Years: Adherence, Effectiveness, and Adverse Effects, Journal of the American Academy of Child & Adolescent Psychiatry, vol.43, issue.5, pp.559-567, 2004.
DOI : 10.1097/00004583-200405000-00009

M. Staquet, R. Hays, and P. Fayers, Quality of Life Assessment in Clinical Trials: Methods and Practice, 1998.

W. Conover and R. Iman, Rank transformations as a bridge between parametric and nonparametric statistics, Am Stat, vol.35, pp.124-129, 1981.

C. Spielberger, Manual for the Strait-Trait Anxiety Inventory for Children, Book Manual for the Strait-Trait Anxiety Inventory for Children, 1973.

D. Safer, J. Zito, and E. Fine, Increased methylphenidate usage for attention deficit disorder in the 1990s, Pediatrics, vol.98, pp.1084-1088, 1996.

C. Frances, G. Hoizey, H. Millart, and T. Trenque, Paediatric methylphenidate (Ritalin??) restrictive conditions of prescription in France, British Journal of Clinical Pharmacology, vol.37, issue.1, pp.115-116, 2004.
DOI : 10.1046/j.1365-2125.2003.01943.x

M. Cyr and C. Brown, Current Drug Therapy Recommendations for the Treatment of Attention Deficit Hyperactivity Disorder, Drugs, vol.56, issue.2, pp.215-223, 1998.
DOI : 10.2165/00003495-199856020-00005

S. Law and R. Schachar, Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder? J Am Acad Child Adolesc Psychiatry, pp.944-951, 1999.

T. Spencer, J. Biederman, M. Harding, O. Donnell, D. Faraone et al., Growth deficits in ADHD children revisited: evidence for disorderassociated growth delays? J Am Acad Child Adolesc Psychiatry, pp.1460-1469, 1996.

W. Cooper, L. Habel, C. Sox, K. Chan, P. Arbogast et al., ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults, New England Journal of Medicine, vol.365, issue.20, pp.1896-1904
DOI : 10.1056/NEJMoa1110212